Compare Cytokinetics Inc (CYTK) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Grab Holdings Ltd. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Grab Holdings Ltd. trades at $3.73 (market cap $14.97B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| CYTK | GRAB | |
|---|---|---|
Market Cap | $10.78B | $14.97B |
Sector | Technology | Technology |
52-Week High | $87.26 | $6.45 |
52-Week Low | $34.31 | $3.27 |
Enterprise Value | $10.88B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
GRAB trades at $3.66, down 0.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance, supported by growth in on-demand and financial services segments. Analyst sentiment is overwhelmingly positive, with 91.67% recommending Buy.
Outlook remains favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and insider selling. The stock offers upside to the average price target of $5.86, though volatility from competitive pressures and macroeconomic headwinds warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
